A Study to Evaluate ALN-AGT01 in Patients With Hypertension
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and
pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 in participants with
hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose
(SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in
hypertensive participants with controlled salt intake, Part D will be a MD phase in
hypertensive participants who are obese, and Part E will be an open-label SD phase with
co-administration of irbesartan in hypertensive patients.